# Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]
Canonical URL: https://biopharmsignal.com/news/EBS/emergent-biosolutions-receives-saudi-food-and-drug-authority-approval-for-acam2000r-smallpox-and-mpox-vaccinia-vaccine-live
Ticker: EBS
Company: Emergent BioSolutions
Source: Emergent BioSolutions
Published: 2026-05-18 12:59 EST
Original Source URL: https://investors.emergentbiosolutions.com
## Summary

GAITHERSBURG, Md., May 18, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS), a global biodefense company, today announced that the Saudi Food and Drug Authority (SFDA) has approved the registration of ACAM2000® [Smallpox and Mpox  (Vaccinia) Vaccine, Live], for the prevention of smallpox

## Article Body
GAITHERSBURG, Md., May 18, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS), a global biodefense company, today announced that the Saudi Food and Drug Authority (SFDA) has approved the registration of ACAM2000® [Smallpox and Mpox  (Vaccinia) Vaccine, Live], for the prevention of smallpox
## Recent Company News
- 2026-05-28 20:01 EST — [Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy](https://biopharmsignal.com/news/EBS/emergent-biosolutions-receives-64-5-million-contract-modification-for-batr-botulism-antitoxin-heptavalent-a-b-c-d-e-f-g-equine-to-support-u-s-biodefense-strategy) — Source: Emergent BioSolutions
- 2026-05-20 11:30 EST — [Emergent BioSolutions to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/EBS/emergent-biosolutions-to-participate-in-upcoming-investor-conferences) — Source: Emergent BioSolutions
- 2026-05-18 12:59 EST — [Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]](https://biopharmsignal.com/news/EBS/emergent-biosolutions-receives-saudi-food-and-drug-authority-approval-for-acam2000r-smallpox-and-mpox-vaccinia-vaccine-live) — Source: Emergent BioSolutions
- 2026-04-30 20:30 EST — [Emergent BioSolutions Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/EBS/emergent-biosolutions-reports-first-quarter-2026-financial-results) — Source: Emergent BioSolutions
- 2026-04-30 11:55 EST — [Emergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to Include Mpox](https://biopharmsignal.com/news/EBS/emergent-biosolutions-receives-approval-from-singapore-health-sciences-authority-for-expanded-indication-of-acam2000r-smallpox-and-mpox-vaccinia-vaccine-live-to-include-mpox) — Source: Emergent BioSolutions
## Related News
- 2026-07-21 20:15 EST — BFRG — [BullFrog AI to Participate in Water Tower Research Fireside Chat on Thursday, July 23, 2026](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-water-tower-research-fireside-chat-on-thursday-jul-78357ce8)
- 2026-07-21 20:05 EST — CLPT — [ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026](https://biopharmsignal.com/news/CLPT/clearpoint-neuro-to-announce-second-quarter-2026-results-august-3-2026-6e4f3c05)
- 2026-07-21 20:05 EST — TCMD — [Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026](https://biopharmsignal.com/news/TCMD/tactile-medical-to-release-second-quarter-of-fiscal-year-2026-financial-results--798d4004)
- 2026-07-21 20:05 EST — PIII — [P3 Health Partners Schedules Second Quarter 2026 Earnings Release and Conference Call](https://biopharmsignal.com/news/PIII/p3-health-partners-schedules-second-quarter-2026-earnings-release-and-conference-6c9bd8a7)
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)